Overview
Cutaneous angiosarcoma is a rare, aggressive malignancy with a poor prognosis 1. Treatment strategies are often adapted from other sarcomas due to limited high-level evidence from randomized controlled trials 1.Diagnosis
No information provided in the abstracts.Management
First-line treatment: Chemoradiotherapy (CRT) is weakly recommended for large (≥5 cm) nonmetastatic tumors 1.
Management of residual lesions post-CRT: Drug modification is preferred over excision 1.
Second-line treatment: Docetaxel, pazopanib, or eribulin are equally considered for paclitaxel-resistant cases 1.
Tumor mutational burden-high cases: Pembrolizumab is weakly recommended 1.
Radiation-associated angiosarcoma: Surgical treatment is favored over CRT 1.
Stewart-Treves syndrome: Treatment is similar to head-and-neck angiosarcoma 1.Special Populations
No information provided in the abstracts.Key Recommendations
Chemoradiotherapy (CRT) is weakly recommended for large (≥5 cm) nonmetastatic cutaneous angiosarcomas 1. (Evidence: Weak)
For residual lesions after CRT, drug modification is preferred over surgical excision 1. (Evidence: Weak)
For cases resistant to paclitaxel, docetaxel, pazopanib, or eribulin should be equally considered 1. (Evidence: Weak)References
1 Fujisawa Y, Yoshioka Y, Yoshino K, Fujimura T, Naito Y, Masuzawa M et al.. Secondary Publication of Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Angiosarcoma 2025. The Journal of dermatology 2025. link